Nintedanib esylate is a potent, oral triple angiokinase inhibitor
developed by Boehringer Ingelheim that targets proangiogenic and
pro-fibrotic pathways mediated by the vascular endothelial growth
factor receptor, fibroblast growth factor receptor and plateletderived
growth factor receptor families, as well as Src and Flt-3
kinases. It was approved for the treatment of idiopathic pulmonary
fibrosis (IPF), a condition in which the lungs become progressively
scarred over time, by the US FDA in October 2014 and by
the EMA in January 2015. The FDA granted nintedanib esylate
fast-track, priority review, orphan product, and breakthrough
designations. The drug was also approved by the EMA in November
2014 for treatment of non-small cell lung cancer in combination
with docetaxel after first-line chemotherapy.
